NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

T.A. Yap, N. Ngoi, E.E. Dumbrava, D.D. Karp, J. Rodon Ahnert, S. Fu, David S. Hong, A. Naing, S. Pant, S.A. Piha-Paul, V. Subbiah, Apostolia M. Tsimberidou, Desirae Dufner, J. Rhudy, S. Gore, S.P. Ivy, Y. Yuan, S.N. Westin, G.B. Mills, F. Meric-Bernstam